Lundbeck to continue alcohol addiction drug trials
Lundbeck will initiate phase-three trials of a drug to treat alcohol dependence.
The company says that the drug – nalmefene – is a novel way of treating the addiction, as it removes the desire to drink more, rather than being aimed at keeping the patients from drinking.
“Nalmefene offers a rare opportunity for us to provide a new and more effective treatment of alcohol dependence, which causes major harm to millions of people worldwide,” said Anders Gersel Pedersen, executive vice president at Lundbeck.
Previous clinical trials have found the drug significantly limits patients alcohol intake and suggest that it is well-tolerated and safe, the company says.
The phase-three trials will study more than 1,800 people and the first set of data from the study is expected in 2011.